Compass Therapeutics (CMPX) Profit After Tax (2018 - 2026)

Compass Therapeutics (CMPX) has 9 years of Profit After Tax data on file, last reported at -$18.3 million in Q1 2026.

• For the quarter ending Q1 2026, Profit After Tax fell 10.12% year-over-year to -$18.3 million; the trailing twelve-month figure through Mar 2026 stood at -$68.1 million (down 23.61% YoY), and the FY2025 full-year result was -$66.4 million, down 34.52% from the prior year.
• Profit After Tax slipped to -$18.3 million in Q1 2026, from -$15.7 million in the prior quarter.
• In the past five years, Profit After Tax ranged from a high of -$7.2 million in Q1 2022 to a low of -$19.9 million in Q2 2025.
• A 5-year average of -$12.7 million and a median of -$12.1 million in 2022 frame the typical range for Profit After Tax.
• Across the five-year window, Profit After Tax tumbled 102.58% in 2022 and rose 18.32% in 2023, its largest moves.
• Tracing CMPX's Profit After Tax over 5 years: stood at -$11.6 million in 2022, then decreased by 12.78% to -$13.1 million in 2023, then fell by 18.4% to -$15.5 million in 2024, then dropped by 1.47% to -$15.7 million in 2025, then retreated by 16.59% to -$18.3 million in 2026.
• Business Quant data shows CMPX's Profit After Tax at -$18.3 million in Q1 2026, -$15.7 million in Q4 2025, and -$14.2 million in Q3 2025.